Viatris Inc. (NASDAQ: VTRS), a leading global pharmaceutical company based in the U.S., has announced the official launch of its nasal spray combination therapy, Dymista (azelastine, fluticasone), in China. This medication is now available to treat moderate to severe seasonal and perennial allergic rhinitis in adults and children aged 12 and above, particularly for those who have shown poor responses to intranasal antihistamines or corticosteroid monotherapy, with or without accompanying ocular symptoms.
Dymista, the sole medication of its kind in China, received marketing approval from the National Medical Products Administration (NMPA) in June 2023. Notably, Dymista’s generic version was approved in China prior to the originator drug, with Changfeng Pharma securing approval for its generic equivalent in 2022. This facilitated the drug’s inclusion in the National Reimbursement Drug List following price negotiations at the end of 2023. Globally, Dymista has been approved in more than 45 markets, marking a significant expansion in its accessibility to patients. – Flcube.com
